Inhibitory Activity of Ranibizumab, Sorafenib, and Pazopanib on Light-Induced Overexpression of Platelet-Derived Growth Factor and Vascular Endothelial Growth Factor a and the Vascular Endothelial Growth Factor a Receptors 1 and 2 and Neuropilin 1 and 2

Abstract

Our in vitro results suggest that multikinase inhibitors have promising properties as a potential antiangiogenic treatment for age-related macular degeneration.

EGFR-Blockade With Erlotinib Reduces EGF and TGF-β2 Expression and the Actin-Cytoskeleton Which Influences Different Aspects of Cellular Migration in Lens Epithelial cells

“…It was shown before, that inhibiting a tyrosin kinase growth-factor receptor causes a downregulation of different growth factors, often not directly connected to the receptor. [52][53][54][55] This seems to happen via an endocrine feedback loop. In a previous study, using a cancer cell line and a monoclonal antibody, the amount of FGF-2 produced by the cells was reduced.…”

Common Sequence Variation in the VEGFC Gene Is Associated with Diabetic Retinopathy and Diabetic Macular Edema

“…Multikinase inhibitors, such as sorafenib and pazopanib, are promising new agents that target a number of tyrosine kinase receptors in the VEGFR family and have significantly reduced the expression of VEGFR-1 and VEGFR-2 in human retinal pigment epithelial cells. 28 Phase IIa therapeutic trials using topical pazopanib eye drops for the treatment of neovascular age-related macular degeneration have shown favorable results. 29 The efficacy of pazopanib for the treatment of DR has so far been limited to a streptozotocin rat model in which topical pazopanib reduced DR-associated blood-retinal-barrier breakdown.…”

Expression and function of PDGF-α in columnar epithelial cells of age-related cataracts patients

“…In elderly patients, however, such self-regulation slowly weakens and the characteristics of columnar epithelial cells are gradually lost (Kernt et al, 2012). However, PDGF-α concentration increases in the aqueous humor.…”